103 related articles for article (PubMed ID: 2470892)
21. Persistent infection of MT-4 cells by human immunodeficiency virus type 1 becomes increasingly likely with in vitro serial passage of wild-type but not nef mutant virus.
Nishino Y; Nakaya T; Fujinaga K; Kishi M; Azuma I; Ikuta K
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2241-51. PubMed ID: 7521392
[TBL] [Abstract][Full Text] [Related]
22. 5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro.
Bouchard J; Walker MC; Leclerc JM; Lapointe N; Beaulieu R; Thibodeau L
Antimicrob Agents Chemother; 1990 Feb; 34(2):206-9. PubMed ID: 1691617
[TBL] [Abstract][Full Text] [Related]
23. Influence of L-lysine amino acid on the HIV-1 RNA replication in vitro.
Butorov EV
Antivir Chem Chemother; 2015 Feb; 24(1):39-46. PubMed ID: 26149265
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by daphnodorins.
Yusa K; Oh-hara T; Tsukahara S; Baba K; Taniguchi M; Kozawa M; Takeuchi S; Hara H; Tsuruo T
Antiviral Res; 1994 Sep; 25(1):57-66. PubMed ID: 7529015
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
[TBL] [Abstract][Full Text] [Related]
26. In vitro anti-human immunodeficiency virus type 1 activity of biliverdin, a bile pigment.
Mori H; Otake T; Morimoto M; Ueba N; Kunita N; Nakagami T; Yamasaki N; Taji S
Jpn J Cancer Res; 1991 Jul; 82(7):755-7. PubMed ID: 1715337
[TBL] [Abstract][Full Text] [Related]
27. Lecithinized superoxide dismutase: an inhibitor of human immunodeficiency virus replication.
Premanathan M; Nakashima H; Igarashi R; Mizushima Y; Yamada K
AIDS Res Hum Retroviruses; 1997 Mar; 13(4):283-90. PubMed ID: 9071427
[TBL] [Abstract][Full Text] [Related]
28. S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation.
Daelemans D; Esté JA; Witvrouw M; Pannecouque C; Jonckheere H; Aquaro S; Perno CF; De Clercq E; Vandamme AM
Mol Pharmacol; 1997 Dec; 52(6):1157-63. PubMed ID: 9396786
[TBL] [Abstract][Full Text] [Related]
29. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
De Clercq E
Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
[TBL] [Abstract][Full Text] [Related]
30. Novel naphthalenedisulfonic acid anti-HIV-1 agents. Synthesis and activity against reverse transcriptase, virus replication and syncytia formation.
Mohan P; Singh R; Baba M
Drug Des Discov; 1991 Nov; 8(1):69-82. PubMed ID: 1725723
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human immunodeficiency virus type-1-induced syncytium formation and cytopathicity by complestatin.
Momota K; Kaneko I; Kimura S; Mitamura K; Shimada K
Biochem Biophys Res Commun; 1991 Aug; 179(1):243-50. PubMed ID: 1715691
[TBL] [Abstract][Full Text] [Related]
32. In vitro anti-HIV-1 virucidal activity of tyrosine-conjugated tri- and dihydroxy bile salt derivatives.
Al-Jabri AA; Wigg MD; Elias E; Lambkin R; Mills CO; Oxford JS
J Antimicrob Chemother; 2000 May; 45(5):617-21. PubMed ID: 10797083
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein.
Slepushkin VA; Kornilaeva GV; Andreev SM; Sidorova MV; Petrukhina AO; Matsevich GR; Raduk SV; Grigoriev VB; Makarova TV; Lukashov VV
Virology; 1993 May; 194(1):294-301. PubMed ID: 7683157
[TBL] [Abstract][Full Text] [Related]
34. Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro.
Montefiori DC; Zhou JY
Antiviral Res; 1991 Jan; 15(1):11-25. PubMed ID: 1709802
[TBL] [Abstract][Full Text] [Related]
35. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus.
Schinazi RF; Chu CK; Babu JR; Oswald BJ; Saalmann V; Cannon DL; Eriksson BF; Nasr M
Antiviral Res; 1990 May; 13(5):265-72. PubMed ID: 1697740
[TBL] [Abstract][Full Text] [Related]
36. Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation.
Kucera LS; Iyer N; Leake E; Raben A; Modest EJ; Daniel LW; Piantadosi C
AIDS Res Hum Retroviruses; 1990 Apr; 6(4):491-501. PubMed ID: 1692729
[TBL] [Abstract][Full Text] [Related]
37. Fuchsin acid selectively inhibits human immunodeficiency virus (HIV) replication in vitro.
Baba M; Schols D; Pauwels R; Balzarini J; De Clercq E
Biochem Biophys Res Commun; 1988 Sep; 155(3):1404-11. PubMed ID: 3178818
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of human immunodeficiency virus type (HIV-1) replication by some diversely functionalized spirocyclopropyl derivatives.
Witvrouw M; Pannecouque C; De Clercq E; Fernández-Alvarez E; Marco JL
Arch Pharm (Weinheim); 1999 May; 332(5):163-6. PubMed ID: 10366901
[TBL] [Abstract][Full Text] [Related]
39. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
40. Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells.
Harakeh S; Jariwalla RJ; Pauling L
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7245-9. PubMed ID: 1698293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
